Who are Ropivacaine, Ketorolac and Adrenaline's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chirocaine ketorolac epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropivacaine-ketorolac-and-adrenaline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ropivacaine, Ketorolac and Adrenaline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ropivacaine, Ketorolac and Adrenaline (Ropivacaine, Ketorolac and Adrenaline) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination with NSAID and vasopressor. Area: Anesthesia and Pain Management.

marketed Local anesthetic combination with NSAID and vasopressor Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline) Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ropivacaine, Ketorolac and Adrenaline (Ropivacaine, Ketorolac and Adrenaline) — University of Aarhus. This combination provides local anesthesia via sodium channel blockade (ropivacaine), pain relief through COX inhibition (ketorolac), and vasoconstriction with sympathomimetic effects (adrenaline).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacaine, Ketorolac and Adrenaline TARGET	Ropivacaine, Ketorolac and Adrenaline	University of Aarhus	marketed	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
Chirocaine ketorolac epinephrine	Chirocaine ketorolac epinephrine	maximiliano barahona vasquez	phase 3	Local anesthetic combination with NSAID and vasopressor	Voltage-gated sodium channels (chirocaine); COX-1/COX-2 (ketorolac); alpha-1 and beta-adrenergic receptors (epinephrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination with NSAID and vasopressor class)

University of Aarhus · 1 drug in this class
maximiliano barahona vasquez · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ropivacaine, Ketorolac and Adrenaline — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-ketorolac-and-adrenaline. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab